1
|
Yang H, Yu H, Stolarzewicz IA, Tang W. Enantioselective Transformations in the Synthesis of Therapeutic Agents. Chem Rev 2023; 123:9397-9446. [PMID: 37417731 DOI: 10.1021/acs.chemrev.3c00010] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/08/2023]
Abstract
The proportion of approved chiral drugs and drug candidates under medical studies has surged dramatically over the past two decades. As a consequence, the efficient synthesis of enantiopure pharmaceuticals or their synthetic intermediates poses a profound challenge to medicinal and process chemists. The significant advancement in asymmetric catalysis has provided an effective and reliable solution to this challenge. The successful application of transition metal catalysis, organocatalysis, and biocatalysis to the medicinal and pharmaceutical industries has promoted drug discovery by efficient and precise preparation of enantio-enriched therapeutic agents, and facilitated the industrial production of active pharmaceutical ingredient in an economic and environmentally friendly fashion. The present review summarizes the most recent applications (2008-2022) of asymmetric catalysis in the pharmaceutical industry ranging from process scales to pilot and industrial levels. It also showcases the latest achievements and trends in the asymmetric synthesis of therapeutic agents with state of the art technologies of asymmetric catalysis.
Collapse
Affiliation(s)
- He Yang
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
| | - Hanxiao Yu
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
| | - Izabela A Stolarzewicz
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
| | - Wenjun Tang
- State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China
- School of Chemistry and Material Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China
| |
Collapse
|
2
|
Feng Y, Zhou Z, Wu S, Lin W, Lu S, Pang X, Xia K, He F, Zhang Q, Yang H, Wang Z. Biocatalytic Asymmetric Reduction of a Sterically Hindered α-Bromo Ketone for the Synthesis of Key Intermediates of Olodaterol. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2023]
Affiliation(s)
- Yahui Feng
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Zihong Zhou
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
- School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510640, P. R. China
| | - Shuming Wu
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Wei Lin
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Songquan Lu
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Xiaolei Pang
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Ke Xia
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Fang He
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Qin Zhang
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
- College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, P. R. China
| | - Hu Yang
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Zhongqing Wang
- School of Pharmacy, Xiangnan University, Chenzhou 423000, Hunan, China
- State Key Laboratory of Anti-Infective Drug Development (NO. 2015DQ780357), Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China
- Department of Process Research and Development, HEC Pharm Group, Dongguan 523871, P. R. China
| |
Collapse
|
3
|
Xie H, Liu H, Zhang Y, Huang E, Feng Y, Xiang X, Fang Q, Peng Z, Dong W, An D. Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.0c00519] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Hongming Xie
- State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China
| | - Haiwang Liu
- The State Key Laboratory of Anti-Infective Drug Development (No. 2015DQ780357), Sunshine Lake Pharma Co. Ltd., Dongguan 523871, P. R. China
| | - Yingjun Zhang
- The State Key Laboratory of Anti-Infective Drug Development (No. 2015DQ780357), Sunshine Lake Pharma Co. Ltd., Dongguan 523871, P. R. China
| | - Enhuo Huang
- The State Key Laboratory of Anti-Infective Drug Development (No. 2015DQ780357), Sunshine Lake Pharma Co. Ltd., Dongguan 523871, P. R. China
| | - Yahui Feng
- HEC Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Xuwen Xiang
- HEC Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Qinghong Fang
- The State Key Laboratory of Anti-Infective Drug Development (No. 2015DQ780357), Sunshine Lake Pharma Co. Ltd., Dongguan 523871, P. R. China
| | - Zhihong Peng
- State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China
| | - Wanrong Dong
- State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China
| | - Delie An
- State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China
| |
Collapse
|
4
|
Breaking Molecular Symmetry through Biocatalytic Reactions to Gain Access to Valuable Chiral Synthons. Symmetry (Basel) 2020. [DOI: 10.3390/sym12091454] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
In this review the recent reports of biocatalytic reactions applied to the desymmetrization of meso-compounds or symmetric prochiral molecules are summarized. The survey of literature from 2015 up to date reveals that lipases are still the most used enzymes for this goal, due to their large substrate tolerance, stability in different reaction conditions and commercial availability. However, a growing interest is focused on the use of other purified enzymes or microbial whole cells to expand the portfolio of exploitable reactions and the molecular diversity of substrates to be transformed. Biocatalyzed desymmetrization is nowadays recognized as a reliable and efficient approach for the preparation of pharmaceuticals or natural bioactive compounds and many processes have been scaled up for multigram preparative purposes, also in continuous-flow conditions.
Collapse
|